Oksaflozan

Из Википедије, слободне енциклопедије
Oksaflozan
(IUPAC) ime
4-propan-2-il-2-[3-(trifluorometil)fenil]morfolin
Klinički podaci
Identifikatori
CAS broj 26629-86-7
ATC kod N06AX10
PubChem[1][2] 432824
ChemSpider[3] 382782
UNII V4WLW77V5Q YesY
KEGG[4] D07340
Hemijski podaci
Formula C14H18F3NO 
Mol. masa 273,29 g/mol
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća  ?
Pravni status Prescription only
Način primene Oralno

Oksaflozan (Confliktan) je antidepresiv i anksiolitik koji je uveden u prodaju 1982. za tretmant depresije, ali je u međuvremenu izašao iz upotrebe.[5][6] On je prolek za N-dealkiloksaflozan, koji deluje kao neselektivni agonist serotoninskih receptora: 5-HT1A (pKi = 7,1), 5-HT2A (pKi = 6,0), i 5-HT2C (pKi = 7,5).[7] Oksaflozan potencijalno ima i antiholinergičko dejstvo pri visokim dozama.[8]

Reference[уреди]

  1. ^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.“. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. ^ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities“. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. ^ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining“. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.  edit
  4. ^ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG“. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H. 
  5. ^ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. стр. 766. ISBN 3-88763-075-0. 
  6. ^ Sittig, Marshall (1988). Pharmaceutical manufacturing encyclopedia. Park Ridge, N.J., U.S.A: Noyes Publications. стр. 1122. ISBN 0-8155-1144-2. 
  7. ^ Leysen DC (February 1999). „Selective 5-HT2C agonists as potential antidepressants“. IDrugs : the Investigational Drugs Journal 2 (2): 109–20. PMID 16160946. 
  8. ^ Dutertre JP, Barbier P, Suc AL, Jonville AP, Autret E (1992). „Oxaflozane overdose in a child“. Journal of Toxicology. Clinical Toxicology 30 (1): 123–6. PMID 1542141. 

Literatura[уреди]

  • Sittig, Marshall (1988). Pharmaceutical manufacturing encyclopedia. Park Ridge, N.J., U.S.A: Noyes Publications. стр. 1122. ISBN 0-8155-1144-2. 
  • Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. стр. 766. ISBN 3-88763-075-0. 
  • Rascol A, Maurel H, David J, Layani M (1974). „[Preliminary clinical results of a new non tricyclic antidepressive drug: oxaflozane]“ (на French). Thérapie 29 (1): 95–9. PMID 4603757. 
  • Hache J, Duchene-Marullaz P, Streichenberger G (1974). „[Pharmacological profile of a new non tricyclic antidepressant: oxaflozane (1,766 Cerm)]“ (на French). Thérapie 29 (1): 81–93. PMID 4849381. 
  • Constantin M, Pognat JF (1979). „Comparative study of oxaflozane urinary metabolism in man, the dog and the rat. Identification of the principal metabolites“. Arzneimittel-Forschung 29 (1): 109–14. PMID 582104. 
  • Bertolino A, palermo M, Porro V (1985). „Oxaflozane, a new nontricyclic antidepressant in the treatment of anxiety-depressions syndromes.“. Acta Ther (11): 209–218. 
  • Aguglia E (1986). „On the therapetic value of axaflozane: Its application in the treatment of emotional disturbances of the anxious-depressive type accompanied by somatic manifestations.“. Acta Ther (12): 259–267. 

Spoljašnje veze[уреди]